×
Friday, December 2, 2022

Jasjit Suri – The Man Behind the Cutting-Edge AI Technology Transforming the Healthcare Sector

Last updated Monday, November 21, 2022 13:16 ET , Source: Jasjit Suri

Dallas, TX , Pakistan, 11/21/2022 / SubmitMyPR /

The use of artificial intelligence (AI) technologies is rapidly expanding in today’s industries, especially the healthcare sector. Many aspects of patient care and administrative operations benefit from the application of AI, which speeds up the process of finding better solutions and overcoming obstacles. While most AI-based healthcare technologies are very applicable to the healthcare sector, the strategies they facilitate can differ considerably between different healthcare organizations.

Benefits of incorporating AI into the healthcare ecosystem include the automation of tasks and the analysis of large and complex data sets of patients, both of which contribute to the provision of higher-quality treatment in less time and at a lower cost.

AI has the potential to automate duties, such as pre-authorizing insurance, following up on delinquent bills, and keeping records, thereby reducing the burden on healthcare personnel and saving money.

AI can sift through mountains of data, gleaning useful information about individual patients and paving the way for future diagnostic analyses. It is crucial for the healthcare ecosystem to quickly gather patient insights to identify significant areas of patient care that need improvement.

Since its inception 50 years ago, AI has played a pivotal role in the diagnosis and treatment of diseases. An American industrialist, innovator, chief technology officer, and scientist Jasjit S. Suri has worked relentlessly to modernize this industry further. Suri has a wide range of skills and experience in the fields of biomedical engineering, industrial computer engineering, computer sciences, software and hardware engineering, clinical and regulatory engineering, and its management. His work, however, is mostly dedicated to exploring the potential applications of AI in the healthcare and biomedical fields.

Suri, a biomedical engineer, and medical imaging specialist hypothesizes that AI-based imaging can be used to characterize the tissue of a COVID-19 patient and categorize the severity of the infection using heatmaps, thereby reducing the timeframe to detect a life-threatening cardiovascular disease. A cardiac MRI, according to Suri’s understanding, can produce a complex three-dimensional image that needs to be evaluated from numerous perspectives before a diagnosis can be made. Here, AI can be utilized to understand and highlight various symptoms for human physicians to look for in a patient’s images, ultimately, speeding up the diagnostic process and getting patients into therapy faster.

Suri is the CEO of AtheroPoint, a medical imaging technology firm that created software that offers a similar diagnostic service for various ailments in different vascular anatomies, including atherosclerosis, atherosclerotic vascular disease, carotid artery disease, aortic disease, renal artery disease, and peripheral artery disease. Because of its widespread use in hospitals before the pandemic, the approach has facilitated the rapid and accurate diagnosis of a wide range of conditions. Dr. Suri, of Global Biomedical Technologies Inc., also provides services for ailments of the non-vascular category, i.e., diseases of thyroid cancer, liver cancer, ovarian cancer, prostate cancer, and neurological cancer areas.

He believes that cardiac issues can be instantly predicted by training the software to detect COVIDinduced heart blockages. Yet another one of Suri’s achievements is the implementation of software for the diagnosis of cardiovascular problems associated with COVID-19.

Suri’s contributions extend beyond AI, from machine learning, and deep learning, to deep hybrid learning and beyond. He has written four books and approximately two hundred articles on AI for sources such as the National Institutes of Health and the National Library of Medicine. His contributions to the fields of bias evaluation of AI systems and the design of “Unseen AI” versus “Seen AI” systems for predicting chronic obstructive pulmonary disease (COPD), Parkinson’s disease (PD), and cardiovascular disease (CVD) ten years from now are also widely praised.

The United States and Europe have granted Suri more than fifty patents. He also served as CTO and COO in the healthcare medical device industry and established connections with numerous diagnostic centers throughout the world. Suri was awarded the President’s Gold medal by the Director General for his leadership role and outstanding credentials in several disciplines.

Suri has introduced the use of some truly remarkable innovations that are redefining the face of healthcare. There have been tremendous strides made in the field of AI, but there are still some significant concerns to be resolved. People like Jasjit Suri are still working tirelessly to revolutionize healthcare and patient experiences by developing and implementing AI technology and machine learning. With Suri and other innovators like him, the medical field is sure to flourish in the years to come.

Media Contact

Organization: SEO Mistress

Contact Person: Dan Sears

Email: [email protected]

Phone: 734-741-1124

Website: https://seomistress.com/

Address 1: 3171 Whitetail Lane, Dallas, TX 75207

City: Dallas

State: Texas

Country: United States


Original Source of the original story >> Jasjit Suri – The Man Behind the Cutting-Edge AI Technology Transforming the Healthcare Sector


This content is published on behalf of the above source. Please contact them directly for any concern related to the above. 

This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.